JP2005529084A - 結晶性パレコキシブナトリウム - Google Patents

結晶性パレコキシブナトリウム Download PDF

Info

Publication number
JP2005529084A
JP2005529084A JP2003576414A JP2003576414A JP2005529084A JP 2005529084 A JP2005529084 A JP 2005529084A JP 2003576414 A JP2003576414 A JP 2003576414A JP 2003576414 A JP2003576414 A JP 2003576414A JP 2005529084 A JP2005529084 A JP 2005529084A
Authority
JP
Japan
Prior art keywords
parecoxib sodium
type
parecoxib
drug substance
anhydrous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003576414A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529084A5 (enExample
Inventor
アーマド・ワイ・シェイク
トマス・アール・ボーチャート
レナード・ジェイ・フェロ
ジェラルド・ディー・ダンザー
Original Assignee
ファルマシア・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファルマシア・コーポレーション filed Critical ファルマシア・コーポレーション
Publication of JP2005529084A publication Critical patent/JP2005529084A/ja
Publication of JP2005529084A5 publication Critical patent/JP2005529084A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2003576414A 2002-03-15 2003-03-12 結晶性パレコキシブナトリウム Pending JP2005529084A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36456702P 2002-03-15 2002-03-15
US41798702P 2002-10-11 2002-10-11
PCT/US2003/007484 WO2003078408A1 (en) 2002-03-15 2003-03-12 Crystalline parecoxib sodium

Publications (2)

Publication Number Publication Date
JP2005529084A true JP2005529084A (ja) 2005-09-29
JP2005529084A5 JP2005529084A5 (enExample) 2006-04-27

Family

ID=28045416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003576414A Pending JP2005529084A (ja) 2002-03-15 2003-03-12 結晶性パレコキシブナトリウム

Country Status (18)

Country Link
US (1) US20030232871A1 (enExample)
EP (1) EP1485362A1 (enExample)
JP (1) JP2005529084A (enExample)
KR (1) KR100763045B1 (enExample)
CN (1) CN1642926A (enExample)
AR (1) AR038985A1 (enExample)
AU (1) AU2003220180A1 (enExample)
BR (1) BR0308431A (enExample)
CA (1) CA2478500A1 (enExample)
CO (1) CO5631437A2 (enExample)
IL (1) IL163780A0 (enExample)
MX (1) MXPA04008932A (enExample)
MY (1) MY148518A (enExample)
NZ (1) NZ535951A (enExample)
PL (1) PL372880A1 (enExample)
RU (1) RU2300529C2 (enExample)
TW (1) TW200400949A (enExample)
WO (1) WO2003078408A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009527460A (ja) * 2005-12-23 2009-07-30 アムジエン・インコーポレーテツド Ａｍｇ７０６の固体形態およびその医薬組成物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003238669A1 (en) * 2003-04-04 2004-10-25 Hetero Drugs Limited Novel crystalline forms of parecoxib sodium
US7268109B2 (en) 2003-10-02 2007-09-11 Elan Pharmaceuticals, Inc. Method for reducing pain
WO2005065684A1 (en) * 2003-12-24 2005-07-21 Pharmacia Corporation Metal salts of parecoxib as prodrugs of the cox-2 inhibitor valdecoxib for the treatment of inflammation, pain and/or fever
ITMI20040019A1 (it) * 2004-01-12 2004-04-12 Univ Bari Derivati isossazolici e loro impiego come inibitori della ciclossigenasi
US7796785B2 (en) * 2005-03-03 2010-09-14 Fujifilm Corporation Image extracting apparatus, image extracting method, and image extracting program
US7989450B2 (en) 2008-01-11 2011-08-02 Universita' Degli Studi Di Bari Functionalized diarylisoxazoles inhibitors of ciclooxygenase
GB0919757D0 (en) * 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
CN105726496B (zh) * 2014-12-12 2019-05-28 湖南科伦药物研究有限公司 一种帕瑞昔布钠冻干粉剂、其制备方法及其粉剂产品
CN105125506A (zh) * 2015-08-18 2015-12-09 上海秀新臣邦医药科技有限公司 一种注射用帕瑞昔布钠及其制备方法
CN106692079A (zh) * 2016-12-26 2017-05-24 上药东英（江苏）药业有限公司 一种帕瑞昔布钠长效冻干粉针制剂
CN106580893A (zh) * 2016-12-26 2017-04-26 上药东英（江苏）药业有限公司 一种帕瑞昔布钠冻干粉针制剂
CN117003769B (zh) * 2023-07-11 2024-11-22 中国科学院宁波材料技术与工程研究所 氯诺昔康复合物、氯诺昔康-小檗碱共晶及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT892791E (pt) * 1996-04-12 2003-06-30 Searle & Co N-¬¬4-(5-metil-3-fenilisoxazol-4-il|fenil|sulfonil-propilamida e seu sal de sodio como pro-farmacos de inibidores de cox-2
KR20000049138A (ko) * 1996-10-15 2000-07-25 윌리암스 로저 에이 신생물의 치료 및 예방에의 시클로옥시게나제-2 저해제의 사용방법
PE20021017A1 (es) * 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
KR20040085135A (ko) * 2001-10-02 2004-10-07 파마시아 코포레이션 벤젠설포닐 화합물의 제조 방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009527460A (ja) * 2005-12-23 2009-07-30 アムジエン・インコーポレーテツド Ａｍｇ７０６の固体形態およびその医薬組成物

Also Published As

Publication number Publication date
IL163780A0 (en) 2005-12-18
MY148518A (en) 2013-04-30
CO5631437A2 (es) 2006-04-28
KR20040095288A (ko) 2004-11-12
WO2003078408A1 (en) 2003-09-25
RU2300529C2 (ru) 2007-06-10
AR038985A1 (es) 2005-02-02
CA2478500A1 (en) 2003-09-25
KR100763045B1 (ko) 2007-10-04
MXPA04008932A (es) 2004-11-26
RU2004127585A (ru) 2005-04-10
PL372880A1 (en) 2005-08-08
CN1642926A (zh) 2005-07-20
AU2003220180A1 (en) 2003-09-29
NZ535951A (en) 2006-02-24
TW200400949A (en) 2004-01-16
EP1485362A1 (en) 2004-12-15
US20030232871A1 (en) 2003-12-18
BR0308431A (pt) 2005-01-18

Similar Documents

Publication Publication Date Title
TWI665190B (zh) ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
JP6386478B2 (ja) メチル｛４，６−ジアミノ−２−［１−（２−フルオロベンジル）−１ｈ−ピラゾロ［３，４−ｂ］ピリジノ−３−イル］ピリミジノ−５−イル｝メチルカルバメートの形態
JP2005529084A (ja) 結晶性パレコキシブナトリウム
TWI545124B (zh) ６，７－不飽合－７－胺甲醯基嗎啡喃衍生物之結晶及其製造方法
US20250361218A1 (en) Agents and methods for treating dysproliferative diseases
TWI537265B (zh) ４－｛［４－（｛［４－（２，２，２－三氟乙氧基）－１，２－苯並異唑－３－基］氧基｝甲基）哌啶－１－基］甲基｝－四氫－２ｈ－吡喃－４－羧酸的多晶型形式
WO2016000568A1 (zh) 一种治疗痛风的化合物
JP2005529933A (ja) キサンチンホスホジエステラーゼｖインヒビター多形体
WO2016145622A1 (zh) 苯并咪唑衍生物及其制备方法和医药用途
TWI815820B (zh) ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式
JP2024524250A (ja) １－エチル－ｎ－（（１，２，３，５，６，７－ヘキサヒドロ－ｓ－インダセン－４－イル）カルバモイル）ピペリジン－４－スルホンアミドの結晶性カリウム塩
CN1711247A (zh) 塞来考昔的前药
ZA200406788B (en) Crystalline parecoxib sodium
WO2013160354A1 (en) Crystalline forms of saxagliptin
CN111315746B (zh) 色氨酸羟化酶抑制剂和包括该抑制剂的药物组合物
CN107056819B (zh) 一种预防和治疗心肌缺血的药物及其制备方法
HK1075049A (en) Crystalline parecoxib sodium
HK1106529A (en) Crystalline parecoxib sodium
HK1106528A (en) Crystalline parecoxib sodium
WO2013166966A1 (zh) 含氟的氘代ω-二苯基脲或其盐的多晶型物
JP2015522591A (ja) 重水素化ω―ジメチル尿素又はその塩の多形物
CA2405741A1 (en) Sodium salt of an azo derivative of 5-aminosalicylic acid
JP2014518236A (ja) ６−（ピペリジン−４−イルオキシ）−２ｈ−イソキノリン−１−オン塩酸塩の多形体
WO2025198588A1 (en) Preparation of compound and crystalline forms thereof
HK1081546A (zh) 塞來考昔的前藥

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060308

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20081111

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20081111

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091005

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100308